Business Context and Reporting Period
This Form 8-K Current Report was filed by Dianthus Therapeutics, Inc. on September 16, 2024. The filing discloses a corporate governance event regarding the appointment of a new director and the associated compensatory arrangements.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and board appointments.
Material Changes
The primary material change reported is the appointment of Steven Romano, M.D., as a Class III director and a member of the Science and Technology Committee, effective September 16, 2024.
Compensatory Arrangements and Management Commentary
- Equity Grant: Dr. Romano received an initial option to purchase 22,000 shares of common stock. The option vests in three equal tranches (one-third) on the first, second, and third anniversaries of the grant date, contingent on continued service.
- Cash Compensation: Dr. Romano will receive $40,000 annually for Board service and $5,000 annually for Science and Technology Committee service. Payments are made quarterly and prorated for partial service periods.
- Future Awards: Dr. Romano is eligible for future annual equity grants in accordance with the Company's Non-Employee Director Compensation Policy.
- Indemnification: A standard indemnification agreement was executed in connection with the appointment.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 22,000 share option granted to Dr. Romano.
- Review the Company's Non-Employee Director Compensation Policy to understand the criteria for future annual equity grants.
- Confirm the total number of authorized shares available for issuance under the Company's equity incentive plans.
- Check for any related party transaction disclosures if Dr. Romano has other affiliations with the Company.